J. Perkins

发表

High-content flow cytometry and temporal data analysis for defining a cellular signature of graft-versus-host disease.

R. Brinkman, M. Gasparetto, Shang-Jung Lee, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.

J. Perkins, K. Fields, G. Elfenbein, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.

B. Djulbegovic, J. Perkins, J. Pidala, 2014, The Cochrane database of systematic reviews.

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

J. Perkins, A. Mishra, J. Lancet, 2017, Clinical lymphoma, myeloma & leukemia.

Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.

J. Perkins, J. Lancet, Ling Zhang, 2013, Leukemia research.

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

J. Perkins, J. Pidala, Jongphil Kim, 2011, International journal of hematology.

Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.

J. Perkins, H. Lazarus, B. Cooper, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency

J. Perkins, D. Sullivan, K. Fields, 1997, Bone Marrow Transplantation.

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

J. Perkins, J. Lancet, E. Padron, 2011 .

Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

J. Perkins, J. Greene, R. Sandin, 2006, Bone Marrow Transplantation.

Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease

J. Perkins, J. Pidala, C. Anasetti, 2010, Bone Marrow Transplantation.

Infliximab for managing steroid-refractory acute graft-versus-host disease.

J. Perkins, J. Pidala, Jongphil Kim, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

J. Perkins, J. Pidala, Jongphil Kim, 2010, Bone Marrow Transplantation.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation

J. Perkins, C. Solano, J. Pidala, 2017, Bone Marrow Transplantation.

Optimization of high-dose therapy for the treatment of patients with metastatic breast cancer

J. Perkins, K. Fields, G. Elfenbein, 1996 .

Relative Contributions of Marrow Microenvironment, Growth Factors, and Stem Cells to Hematopoiesis in Vivo in Man

J. Perkins, G. Elfenbein, W. Janssen, 1995, Annals of the New York Academy of Sciences.

High-Dose Chemotherapy and Bone Marrow Transplantation

J. Perkins, G. Yee, 1991 .

276 Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome

J. Perkins, J. Lancet, Luxi Zhang, 2011 .

Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.

J. Perkins, K. Fields, G. Elfenbein, 1997, The American journal of the medical sciences.

Voriconazole Provides Effective Prophylaxis for Invasive Fungal Infection in Patients Receiving Glucocorticoid Therapy for Graft-Versus-Host Disease

M. Schell, J. Perkins, C. Anasetti, 2009, Bone Marrow Transplantation.

Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.

J. Perkins, L. Kronish, K. Fields, 1993, Seminars in oncology.

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality

J. Perkins, J. Pidala, Jongphil Kim, 2011, Haematologica.

Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity

J. Perkins, J. Pidala, C. Anasetti, 2011, Bone Marrow Transplantation.

ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.

J. Perkins, J. Pidala, C. Anasetti, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ifosfamide, carboplatin, and etoposide in combination for induction and high‐dose chemotherapy: focus on breast cancer and lymphoma

G. Lyman, J. Perkins, L. Kronish, 1992, Hematological oncology.

Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10‐year experience at single institution

J. Perkins, J. Pidala, Jongphil Kim, 2010, American journal of hematology.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

J. Perkins, J. Pidala, J. Pinilla-Ibarz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.

J. Perkins, K. Fields, G. Elfenbein, 1993, Seminars in oncology.

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids

J. Perkins, J. Pidala, C. Anasetti, 2011, Haematologica.

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience

J. Perkins, J. Pidala, A. Mishra, 2015, Bone Marrow Transplantation.

Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.

J. Perkins, A. Mishra, J. Lancet, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

H. Jim, J. Perkins, J. Pidala, 2012, Haematologica.

A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.

J. Perkins, W. Janssen, D. Sullivan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

J. Perkins, J. Pidala, Jongphil Kim, 2010, Journal of hematology & oncology.

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission

J. Perkins, J. Pidala, C. Anasetti, 2014, Bone Marrow Transplantation.

Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.

J. Perkins, D. Sullivan, J. Pidala, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes

L. Shaw, J. Perkins, C. Anasetti, 2011, Bone Marrow Transplantation.

Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.

J. Perkins, W. Janssen, J. Pidala, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Parenteral Ondansetron for the Treatment of Chemotherapy‐ and Radiation‐Induced Nausea and Vomiting

J. Perkins, P. Burnette, J. Perkins, 1992, Pharmacotherapy.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study

P. Hari, J. Perkins, J. Lipton, 2017, British journal of haematology.

Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

Daohai Yu, J. Perkins, J. Lancet, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.

J. Perkins, J. Pidala, Jongphil Kim, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma

J. Perkins, T. Nishihori, M. Alsina, 2014, Bone Marrow Transplantation.

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

J. Perkins, W. Janssen, D. Sullivan, 2010, Bone Marrow Transplantation.

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

J. Perkins, D. Sullivan, L. Brand, 2007 .

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

J. Perkins, J. Pidala, A. Mishra, 2020, Leukemia & lymphoma.

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

J. Perkins, W. Janssen, C. Anasetti, 2006 .

Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization

M. Schell, J. Perkins, J. Pidala, 2013, Bone Marrow Transplantation.

High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.

J. Perkins, L. Kronish, K. Fields, 1994, Seminars in oncology.

Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships.

J. Perkins, K. Fields, G. Elfenbein, 1995, Seminars in oncology.

Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: Clinical and economic outcomes

J. Perkins, C. Anasetti, H. Fernandez, 2012, American journal of hematology.

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival

M. Schell, J. Perkins, Jongphil Kim, 2009 .

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

H. Jim, J. Perkins, J. Pidala, 2011 .

Are matched unrelated donor transplants justified for AML in CR1?

J. Perkins, C. Anasetti, M. Nieder, 2006, Best practice & research. Clinical haematology.

Pharmacists' roles in oncology pharmacy services: Results of a global survey

J. Perkins, A. Chan, L. Holle, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality.

J. Perkins, W. Janssen, C. Anasetti, 2005 .

Effectiveness of a pharmacy teaching certificate program offered to practicing pharmacists.

Gwendolyn A. Wantuch, Kamila A. Dell, J. Perkins, 2019, Currents in pharmacy teaching & learning.

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

J. Perkins, C. Anasetti, H. Fernandez, 2011 .

Retrospective Comparison Of Secondary Mobilization Strategies In Candidates For Autologous Hematopoietic Cell Transplantion With A Focus On Resource Utilization: Plerixafor+G-CSF Versus Other Regimens

J. Perkins, K. Daily, C. Anasetti, 2010 .

Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).

J. Perkins, W. Janssen, C. Anasetti, 2006 .

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

J. Perkins, D. Sullivan, Jongphil Kim, 2011, Clinical Cancer Research.

Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.

J. Perkins, Jongphil Kim, B. Yue, 2015, Clinical lymphoma, myeloma & leukemia.

Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.

J. Perkins, K. Fields, G. Elfenbein, 1996, Bone Marrow Transplantation.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

J. Perkins, J. Pidala, J. Pinilla-Ibarz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IFOSFAMIDE, CARBOPLATIN, A N D ETOPOSIDE IN CHEMOTHERAPY: FOCUS O N BREAST CANCER A N D LYMPHOMA COMBINATION FOR INDUCTION A N D HIGH-DOSE

G. Lyman, J. Perkins, L. Kronish, 2006 .

Enhancing Student Knowledge Through a Comprehensive Oncology Simulation

Erini S. Serag-Bolos, J. Perkins, Melissa Chudow, 2018, American Journal of Pharmaceutical Education.